In the news
New frontier in biology: harnessing the power of the repeatome with Dennis Zaller
| Biotech2050 podcast
ROME honored in Endpoints 11: The top private biotechs in pursuit of new drugs
| Endpoints News
The Mysterious Dark Genome: Panel Featuring Rosana Kapeller, CEO of ROME
| World Medical Innovation Forum
The "Dark Genome" with Dr. Rosana Kapeller-Lieberman
| GV "Theory and Practice" podcast
Kapeller's ROME bags $77M to strike gold in the backwaters of the genome
| Fierce Biotech
Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry
| MassBio
ROME founder Rosana Kapeller recruits a CSO from the senior ranks of a major league R&D team
| Endpoints News
Companies Strain to Outdo Each Other with Work-from-Home Perks (Think Ukuleles)
| Wall Street Journal
From Rio to Rome: Rosanna Kapeller on The Long Run
| The Timmerman Report
At ROME Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs
| Xconomy
ROME Therapeutics launches to probe junk DNA for cancer drug discovery
| C&EN
ROME Therapeutics debuts with $50M and Rosana Kapeller at the helm
| Fierce Biotech
GV joins $50 million round in ROME Therapeutics to research ‘junk DNA’ for cancer therapies
| VentureBeat
Nimbus founder Rosana Kapeller has a new company, with $50M and an eye on the ‘repeatome’
| Endpoints News